Pemphigoid. Bullous and cicatricial

Area of Science:

• Dermatology
• Immunology
• Autoimmune Diseases

Background:

• Bullous pemphigoid (BP) is a blistering skin disease primarily affecting the elderly.
• It is characterized by autoantibodies directed against basal cell hemidesmosome antigens.
• Cicatricial pemphigoid (CP) presents similar immunologic characteristics but with distinct clinical outcomes.

Purpose of the Study:

• To describe the immunologic basis of bullous pemphigoid.
• To differentiate bullous pemphigoid from cicatricial pemphigoid.
• To outline the treatment strategies for both conditions.

Main Methods:

• Review of existing literature on bullous pemphigoid and cicatricial pemphigoid.
• Immunological analysis of autoantibodies targeting basal cell hemidesmosome antigens.
• Clinical assessment of disease presentation and treatment response.

Main Results:

• BP involves autoantibodies against 230 kD and 166-180 kD hemidesmosome antigens, leading to subepidermal blistering.
• CP may involve similar antigens, but its scarring sequelae, particularly mucosal, are more severe.
• Conservative corticosteroid therapy is often effective for BP, while CP may necessitate intensive immunosuppression with agents like cyclophosphamide.

Conclusions:

• Bullous pemphigoid is an autoimmune blistering disease typically manageable with corticosteroids.
• Cicatricial pemphigoid poses a greater therapeutic challenge due to its potential for severe scarring and requires more aggressive immunosuppressive treatment.
• Further research is needed to clarify antigen involvement in cicatricial pemphigoid.